168 related articles for article (PubMed ID: 22177533)
1. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells.
Stovold R; Blackhall F; Meredith S; Hou J; Dive C; White A
Lung Cancer; 2012 Jun; 76(3):263-8. PubMed ID: 22177533
[TBL] [Abstract][Full Text] [Related]
2. Irradiation Decreases the Neuroendocrine Biomarker Pro-Opiomelanocortin in Small Cell Lung Cancer Cells In Vitro and In Vivo.
Meredith SL; Bryant JL; Babur M; Riddell PW; Behrouzi R; Williams KJ; White A
PLoS One; 2016; 11(2):e0148404. PubMed ID: 26848743
[TBL] [Abstract][Full Text] [Related]
3. Small cell lung carcinoma with marked bronchial epithelial involvement.
Rosen Y; Durie NM
Int J Surg Pathol; 2011 Aug; 19(4):538-43. PubMed ID: 21632633
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients.
Stovold R; Meredith SL; Bryant JL; Babur M; Williams KJ; Dean EJ; Dive C; Blackhall FH; White A
Br J Cancer; 2013 Apr; 108(8):1704-11. PubMed ID: 23519056
[TBL] [Abstract][Full Text] [Related]
5. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.
Hamilton G; Hochmair M; Rath B; Klameth L; Zeillinger R
Cell Adh Migr; 2016 Jul; 10(4):360-7. PubMed ID: 26919626
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
7. Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers.
Denlinger CE; Ikonomidis JS; Reed CE; Spinale FG
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):505-13. PubMed ID: 20723721
[No Abstract] [Full Text] [Related]
8. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
9. Expression of nicotinic receptors in normal and tumoral pulmonary neuroendocrine cells (PNEC).
Sartelet H; Maouche K; Totobenazara JL; Petit J; Burlet H; Monteau M; Tournier JM; Birembaut P
Pathol Res Pract; 2008; 204(12):891-8. PubMed ID: 18667281
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.
Hamilton G; Rath B
Adv Exp Med Biol; 2017; 994():229-245. PubMed ID: 28560677
[TBL] [Abstract][Full Text] [Related]
11. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
[TBL] [Abstract][Full Text] [Related]
12. Lung tumours with neuroendocrine differentiation.
Travis WD
Eur J Cancer; 2009 Sep; 45 Suppl 1():251-66. PubMed ID: 19775623
[No Abstract] [Full Text] [Related]
13. Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation.
Ishii J; Sato H; Yazawa T; Shishido-Hara Y; Hiramatsu C; Nakatani Y; Kamma H
Pathol Int; 2014 Sep; 64(9):415-22. PubMed ID: 25243889
[TBL] [Abstract][Full Text] [Related]
14. Investigation of proNT/NMN secretion from small cell lung carcinoma cells using a mouse xenograft model.
Wakabayashi-Nakao K; Maruyama K; Ishii H; Muramatsu K; Hatakeyama K; Ohshima K; Ogura S; Nakajima T; Yamaguchi K; Mochizuki T
Oncol Rep; 2012 Oct; 28(4):1181-6. PubMed ID: 22825476
[TBL] [Abstract][Full Text] [Related]
15. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.
Sutherland KD; Proost N; Brouns I; Adriaensen D; Song JY; Berns A
Cancer Cell; 2011 Jun; 19(6):754-64. PubMed ID: 21665149
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.
Kudo K; Ohyanagi F; Horiike A; Miyauchi E; Yanagitani N; Hoshi R; Satoh Y; Motoi N; Hamanaka W; Ishikawa Y; Mun M; Sakao Y; Okumura S; Nakagawa K; Horai T; Nishio M
Lung Cancer; 2011 Dec; 74(3):401-4. PubMed ID: 21529988
[TBL] [Abstract][Full Text] [Related]
17. Small-cell lung cancer: an update on targeted therapies.
Joshi M; Ayoola A; Belani CP
Adv Exp Med Biol; 2013; 779():385-404. PubMed ID: 23288650
[TBL] [Abstract][Full Text] [Related]
18. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
Semenova EA; Nagel R; Berns A
Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
[TBL] [Abstract][Full Text] [Related]
19. FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer.
Kim KB; Kim Y; Rivard CJ; Kim DW; Park KS
Cancer Res; 2020 Nov; 80(22):5051-5062. PubMed ID: 32973083
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.
Ma PC; Blaszkowsky L; Bharti A; Ladanyi A; Kraeft SK; Bruno A; Skarin AT; Chen LB; Salgia R
Anticancer Res; 2003; 23(1A):49-62. PubMed ID: 12683352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
